Bruker Launches Infrared Imaging Microscope for Pharma and Life Science Research
08 1월 2025 - 9:00PM
Business Wire
Groundbreaking LUMOS II ILIM QCL-based IR
microscope sets new standards in speed and resolution
Bruker Corporation (Nasdaq: BRKR) today announced the launch of
the LUMOS™ II ILIM, a quantum cascade laser (QCL) based
infrared imaging microscope. The new LUMOS II ILIM redefines
performance standards, enabling pharma and life science researchers
to capture ultrafast IR images of expansive areas with enhanced
spatial resolution.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20250108014369/en/
LUMOS™ II ILIM quantum cascade laser
(QCL) based infrared imaging microscope for pharma and life science
research (Photo: Business Wire)
The LUMOS II ILIM features a patented coherence reduction
method for infrared laser imaging essentially free from artifacts
in both transmission and reflection mode. With a very large field
of view and complete automation, it allows for the rapid
determination of chemical complexity in biological tissues.
Dr. Guillaume Mabilleau, Clinical Bone Pathologist at Centre
Hospitalier Universitaire Angers in France, stated: “I am impressed
by the speed of this microscope for high quality infrared imaging
of biological samples. The ease of operation and high throughput
achieved with QCL technology is a game changer for clinical
research. We are exploring the new perspectives this research tool
opens for improving diagnosis and treatment of bone disease.”
Using AI-powered data evaluation, LUMOS II ILIM workflows allow
for discoveries in life science, pharma and disease research.
Integration with Bruker’s MALDI Imaging methods enable multimodal
imaging to characterize tissues with enhanced analytical depth. The
LUMOS II ILIM can also be used for rapid pharmaceutical tablet
inspection and particle identification, including automated
sampling. Users can harness a Python interface to adapt the LUMOS
II ILIM to specific requirements and custom workflows. To learn
more about LUMOS II ILIM, please visit:
https://www.bruker.com/ILIM.
About Bruker Corporation – Leader of the Post-Genomic Era
(Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough
post-genomic discoveries and develop new applications that improve
the quality of human life. Bruker’s high performance scientific
instruments and high value analytical and diagnostic solutions
enable scientists to explore life and materials at molecular,
cellular, and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, improved productivity,
and customer success in post-genomic life science molecular and
cell biology research, in applied and biopharma applications, in
microscopy and nanoanalysis, as well as in industrial and cleantech
research, and next-gen semiconductor metrology in support of AI.
Bruker offers differentiated, high-value life science and
diagnostics systems and solutions in preclinical imaging, clinical
phenomics research, proteomics and multiomics, spatial and
single-cell biology, functional structural and condensate biology,
as well as in clinical microbiology and molecular diagnostics. For
more information, please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250108014369/en/
Investor Contact: Joe Kostka Director, Investor Relations
Bruker Corporation T: +1 (978) 313-5800 E:
Investor.Relations@bruker.com Media Contact: Natalie Spahl
Head of Global Marketing Bruker Optics Division T: +49 173 9662425
E: Natalie.spahl@bruker.com
Bruker (NASDAQ:BRKR)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Bruker (NASDAQ:BRKR)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
